Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8531012rdf:typepubmed:Citationlld:pubmed
pubmed-article:8531012lifeskim:mentionsumls-concept:C0003241lld:lifeskim
pubmed-article:8531012lifeskim:mentionsumls-concept:C0039082lld:lifeskim
pubmed-article:8531012pubmed:issue5lld:pubmed
pubmed-article:8531012pubmed:dateCreated1996-1-29lld:pubmed
pubmed-article:8531012pubmed:abstractTextWe surveyed the frequency of reported infections and target autoantigens in 56 Guillain Barré syndrome (GBS) patients by detecting antibodies to myelin and microbes. Sulfatide (43%), cardiolipin (48%), GD1a (15%), SGPG (11%), and GM3 (11%) antibodies were the most frequently detected heterogenous autoantibodies. A wide spectrum of antimicrobial IgG and IgM antibodies were also detected; mumps-specific IgG (66%), adenovirus-specific IgG (52%), varicella-zoster virus-specific IgG (46%), and S. pneumoniae serotype 7-specific IgG (45%) were the most prevalent. Our results indicate that polyclonal expansion of physiologic and pathologic antibodies and/or molecular mimicry likely occurs following infection and is related to other autoimmune factors in the etiology of GBS. Although no single definitive myelin-specific autoantibody was identified, our results suggest a unique pattern of reactivity against autoantigens.lld:pubmed
pubmed-article:8531012pubmed:languageenglld:pubmed
pubmed-article:8531012pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8531012pubmed:citationSubsetIMlld:pubmed
pubmed-article:8531012pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8531012pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8531012pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8531012pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8531012pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8531012pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8531012pubmed:statusMEDLINElld:pubmed
pubmed-article:8531012pubmed:issn0887-8013lld:pubmed
pubmed-article:8531012pubmed:authorpubmed-author:LinH CHClld:pubmed
pubmed-article:8531012pubmed:authorpubmed-author:YouinouPPlld:pubmed
pubmed-article:8531012pubmed:authorpubmed-author:ShoenfeldYYlld:pubmed
pubmed-article:8531012pubmed:authorpubmed-author:BarkeJJlld:pubmed
pubmed-article:8531012pubmed:authorpubmed-author:LorberMMlld:pubmed
pubmed-article:8531012pubmed:authorpubmed-author:TanneDDlld:pubmed
pubmed-article:8531012pubmed:authorpubmed-author:SutjitaMMlld:pubmed
pubmed-article:8531012pubmed:authorpubmed-author:AlosachieIIlld:pubmed
pubmed-article:8531012pubmed:authorpubmed-author:GilburdBBlld:pubmed
pubmed-article:8531012pubmed:authorpubmed-author:TerryberryJJlld:pubmed
pubmed-article:8531012pubmed:issnTypePrintlld:pubmed
pubmed-article:8531012pubmed:volume9lld:pubmed
pubmed-article:8531012pubmed:ownerNLMlld:pubmed
pubmed-article:8531012pubmed:authorsCompleteNlld:pubmed
pubmed-article:8531012pubmed:pagination308-19lld:pubmed
pubmed-article:8531012pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:8531012pubmed:meshHeadingpubmed-meshheading:8531012-...lld:pubmed
pubmed-article:8531012pubmed:meshHeadingpubmed-meshheading:8531012-...lld:pubmed
pubmed-article:8531012pubmed:meshHeadingpubmed-meshheading:8531012-...lld:pubmed
pubmed-article:8531012pubmed:meshHeadingpubmed-meshheading:8531012-...lld:pubmed
pubmed-article:8531012pubmed:meshHeadingpubmed-meshheading:8531012-...lld:pubmed
pubmed-article:8531012pubmed:meshHeadingpubmed-meshheading:8531012-...lld:pubmed
pubmed-article:8531012pubmed:meshHeadingpubmed-meshheading:8531012-...lld:pubmed
pubmed-article:8531012pubmed:meshHeadingpubmed-meshheading:8531012-...lld:pubmed
pubmed-article:8531012pubmed:meshHeadingpubmed-meshheading:8531012-...lld:pubmed
pubmed-article:8531012pubmed:meshHeadingpubmed-meshheading:8531012-...lld:pubmed
pubmed-article:8531012pubmed:meshHeadingpubmed-meshheading:8531012-...lld:pubmed
pubmed-article:8531012pubmed:meshHeadingpubmed-meshheading:8531012-...lld:pubmed
pubmed-article:8531012pubmed:meshHeadingpubmed-meshheading:8531012-...lld:pubmed
pubmed-article:8531012pubmed:meshHeadingpubmed-meshheading:8531012-...lld:pubmed
pubmed-article:8531012pubmed:meshHeadingpubmed-meshheading:8531012-...lld:pubmed
pubmed-article:8531012pubmed:meshHeadingpubmed-meshheading:8531012-...lld:pubmed
pubmed-article:8531012pubmed:meshHeadingpubmed-meshheading:8531012-...lld:pubmed
pubmed-article:8531012pubmed:meshHeadingpubmed-meshheading:8531012-...lld:pubmed
pubmed-article:8531012pubmed:meshHeadingpubmed-meshheading:8531012-...lld:pubmed
pubmed-article:8531012pubmed:meshHeadingpubmed-meshheading:8531012-...lld:pubmed
pubmed-article:8531012pubmed:year1995lld:pubmed
pubmed-article:8531012pubmed:articleTitleMyelin- and microbe-specific antibodies in Guillain-Barré syndrome.lld:pubmed
pubmed-article:8531012pubmed:affiliationSpecialty Laboratories, Santa Monica, CA 90404-3900, USA.lld:pubmed
pubmed-article:8531012pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8531012lld:pubmed